The observed lack of evidence for an effect of ASM overexpression on sensitization of glioma cells to therapy is paralleled by the worse survival probability of glioblastoma patients with high levels of ASM in the TCGA database (Fig. 1D). The gene discussed is SMPD1; the disease is glioblastoma.